Pilot HCV Direct Acting Antiviral Therapy and Metabolism

NCT02734173 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: ABT450r-ABT267-ABT333 +/- Ribavirin

Sponsor

Ottawa Hospital Research Institute

Collaborators

[object Object]